Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Haematologica|February 16, 2023
Venetoclax response prediction in acute myeloid leukemia: are we <i>Finnish</i>-ed with uncertainty?Brett Stevens, Daniel A Pollyea
Leukemia & Lymphoma|November 2, 2022
Lower intensity regimens for acute myeloid leukemia: opportunities and challengesMamoon Ahmed, Daniel A Pollyea
Cancer|December 30, 2022
Top advances of the year: LeukemiaAndrew Kent, Daniel A Pollyea
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AMLAnagha Inguva, Daniel A Pollyea
Current Opinion in Hematology|January 18, 2019
Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?Daniel A Pollyea, Craig T Jordan
Current Opinion in Hematology|January 3, 2020
Hypomethylating agents with venetoclax: have we discovered the holy grail?Jonathan A Gutman, Daniel A Pollyea
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive ChemotherapyCourtney D DiNardo, Daniel A Pollyea
Pharmacotherapy|October 5, 2017
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid LeukemiaLindsay C Stansfield, Daniel A Pollyea
American Journal of Hematology|July 1, 2020
Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemiaAllison M Bock, Daniel A Pollyea
Blood|February 5, 2017
Therapeutic targeting of acute myeloid leukemia stem cellsDaniel A Pollyea, Craig T Jordan
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Haematologica|February 16, 2023
Venetoclax response prediction in acute myeloid leukemia: are we <i>Finnish</i>-ed with uncertainty?Brett Stevens, Daniel A Pollyea
Leukemia & Lymphoma|November 2, 2022
Lower intensity regimens for acute myeloid leukemia: opportunities and challengesMamoon Ahmed, Daniel A Pollyea
Cancer|December 30, 2022
Top advances of the year: LeukemiaAndrew Kent, Daniel A Pollyea
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AMLAnagha Inguva, Daniel A Pollyea
Current Opinion in Hematology|January 18, 2019
Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?Daniel A Pollyea, Craig T Jordan
Current Opinion in Hematology|January 3, 2020
Hypomethylating agents with venetoclax: have we discovered the holy grail?Jonathan A Gutman, Daniel A Pollyea
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Beyond Survival: The US Food and Drug Administration Confirms Surrogate End Points for Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive ChemotherapyCourtney D DiNardo, Daniel A Pollyea
Pharmacotherapy|October 5, 2017
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid LeukemiaLindsay C Stansfield, Daniel A Pollyea
American Journal of Hematology|July 1, 2020
Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemiaAllison M Bock, Daniel A Pollyea
Blood|February 5, 2017
Therapeutic targeting of acute myeloid leukemia stem cellsDaniel A Pollyea, Craig T Jordan
Pageof 18